All In MedTech

FDA Clearance Tracker · P100049-S033

LINX Reflux Management System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 4, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 4, 2022

Approved

Time to decision

179 days

Received Apr 8, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P100049-S033
Device name
LINX Reflux Management System
Applicant
Torax Medical
Applicant location
Cincinnati, OH
Received
Apr 8, 2022
Decided
Oct 4, 2022
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P100049

Device type

Device class
Class III

Every decision under product code LEI

FDA's approval statement

As written in FDA's record.

Approval for the following labeling updates: 1) inclusion of final post-approval study results; 2) addition of a precaution based on RELIEF study results; 3) addition of “swallow-induced syncope to the list of adverse events; and 4) revised registered/trademark status.

Source documents

Other decisions for Torax Medical

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.